169 related articles for article (PubMed ID: 24252546)
1. SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.
Atobe M; Naganuma K; Kawanishi M; Morimoto A; Kasahara K; Ohashi S; Suzuki H; Hayashi T; Miyoshi S
Bioorg Med Chem Lett; 2013 Dec; 23(24):6569-76. PubMed ID: 24252546
[TBL] [Abstract][Full Text] [Related]
2. Hit-to-lead optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as a novel class of EP1 receptor antagonists.
Atobe M; Naganuma K; Kawanishi M; Morimoto A; Kasahara K; Ohashi S; Suzuki H; Hayashi T; Miyoshi S
Bioorg Med Chem Lett; 2013 Nov; 23(22):6064-7. PubMed ID: 24094816
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-(1H-indazol-1-yl)-thiazole derivatives as selective EP(1) receptor antagonists for treatment of overactive bladder by core structure replacement.
Atobe M; Naganuma K; Kawanishi M; Morimoto A; Kasahara K; Ohashi S; Suzuki H; Hayashi T; Miyoshi S
Bioorg Med Chem Lett; 2014 Mar; 24(5):1327-33. PubMed ID: 24508133
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel pyrazole acid antagonists for the EP1 receptor.
McKeown SC; Hall A; Giblin GM; Lorthioir O; Blunt R; Lewell XQ; Wilson RJ; Brown SH; Chowdhury A; Coleman T; Watson SP; Chessell IP; Pipe A; Clayton N; Goldsmith P
Bioorg Med Chem Lett; 2006 Sep; 16(18):4767-71. PubMed ID: 16843659
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel 2-(1H-pyrazolo[3,4-b]pyridin-1-yl)thiazole derivative as an EP
Atobe M; Naganuma K; Kawanishi M; Hayashi T; Suzuki H; Nishida M; Arai H
Bioorg Med Chem Lett; 2018 Aug; 28(14):2408-2412. PubMed ID: 29934246
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel pyrazolo[1,5-a]pyridine-based EP
Nishigaya Y; Umei K; Saito Y; Watanabe H; Kondo T; Kondo A; Kawamura N; Tatani K; Kohno Y; Tanaka N; Seto S
Bioorg Med Chem Lett; 2017 Sep; 27(17):4044-4050. PubMed ID: 28784294
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of compounds which contain pyrazole, thiazole and naphthalene ring as antitumor agents.
Yuan JW; Wang SF; Luo ZL; Qiu HY; Wang PF; Zhang X; Yang YA; Yin Y; Zhang F; Zhu HL
Bioorg Med Chem Lett; 2014 May; 24(10):2324-8. PubMed ID: 24731281
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor.
Chambers LJ; Stevens AJ; Moses AP; Michel AD; Walter DS; Davies DJ; Livermore DG; Fonfria E; Demont EH; Vimal M; Theobald PJ; Beswick PJ; Gleave RJ; Roman SA; Senger S
Bioorg Med Chem Lett; 2010 May; 20(10):3161-4. PubMed ID: 20399651
[TBL] [Abstract][Full Text] [Related]
9. 1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists.
Tabrizi MA; Baraldi PG; Preti D; Romagnoli R; Saponaro G; Baraldi S; Moorman AR; Zaid AN; Varani K; Borea PA
Bioorg Med Chem; 2008 Mar; 16(5):2419-30. PubMed ID: 18077171
[TBL] [Abstract][Full Text] [Related]
10. 2-(1H-Pyrazol-1-yl)acetic acids as chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes (CRTh2) antagonists.
Andrés M; Bravo M; Buil MA; Calbet M; Castillo M; Castro J; Eichhorn P; Ferrer M; Lehner MD; Moreno I; Roberts RS; Sevilla S
Eur J Med Chem; 2014 Jan; 71():168-84. PubMed ID: 24292338
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel 1,2,3,6-tetrahydropyridyl-substituted benzo[d]thiazoles: Lead generation and optimization toward potent and orally active EP
Umei K; Nishigaya Y; Tatani K; Kohno Y; Tanaka N; Seto S
Bioorg Med Chem; 2017 Jul; 25(13):3406-3430. PubMed ID: 28483455
[TBL] [Abstract][Full Text] [Related]
14. Novel pyrazolo[1,5-a]pyridines as orally active EP
Umei K; Nishigaya Y; Kondo A; Tatani K; Tanaka N; Kohno Y; Seto S
Bioorg Med Chem; 2017 May; 25(9):2635-2642. PubMed ID: 28342692
[TBL] [Abstract][Full Text] [Related]
15. Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.
Duan LM; Yu HY; Li YL; Jia CJ
Bioorg Med Chem; 2015 Sep; 23(18):6111-7. PubMed ID: 26319621
[TBL] [Abstract][Full Text] [Related]
16. 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.
Pennell AM; Aggen JB; Sen S; Chen W; Xu Y; Sullivan E; Li L; Greenman K; Charvat T; Hansen D; Dairaghi DJ; Wright JJ; Zhang P
Bioorg Med Chem Lett; 2013 Mar; 23(5):1228-31. PubMed ID: 23374868
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.
Takahashi Y; Hashizume M; Shin K; Terauchi T; Takeda K; Hibi S; Murata-Tai K; Fujisawa M; Shikata K; Taguchi R; Ino M; Shibata H; Yonaga M
J Med Chem; 2012 Oct; 55(19):8450-63. PubMed ID: 22971011
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of some new pyrazole-based 1,3-thiazoles and 1,3,4-thiadiazoles as anticancer agents.
Dawood KM; Eldebss TM; El-Zahabi HS; Yousef MH; Metz P
Eur J Med Chem; 2013; 70():740-9. PubMed ID: 24231309
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and SAR study of novel 4,5-dihydropyrazole-Thiazole derivatives with anti-inflammatory activities for the treatment of sepsis.
Zhang Z; Cao P; Fang M; Zou T; Han J; Duan Y; Xu H; Yang X; Li QS
Eur J Med Chem; 2021 Dec; 225():113743. PubMed ID: 34403978
[TBL] [Abstract][Full Text] [Related]
20. Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists.
Elzein E; Kalla R; Li X; Perry T; Parkhill E; Palle V; Varkhedkar V; Gimbel A; Zeng D; Lustig D; Leung K; Zablocki J
Bioorg Med Chem Lett; 2006 Jan; 16(2):302-6. PubMed ID: 16275090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
